Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
  • A61K9/0007—Effervescent
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
  • A23L27/82—Acid flavourants

Definitions

• the invention relates to effervescent mixtures containing at least one acidic, insoluble or slightly soluble pharmaceutical active ingredient in the form of its soluble alkali metal salt or lysinate.
• pharmaceutical active ingredients are, for example, organic derivatives of acetic acid or propionic acid, for example ibuprofen, naproxen, diclofenac, butabarbital, phenobarbital, cefazolin, diatrizoate, ethacrynate, flurbiprofen, sulfacetamide or hetacillin.
• the acidic active ingredients cannot, as a rule, be obtained in finely disperse or colloidal form and are therefore preferably administered as their potassium salts (for example hetacillin) or lysinates (for example ibuprofen) or as their sodium salts (including ibuprofen and most of the other active ingredients mentioned above) in solution.
• their potassium salts for example hetacillin
• lysinates for example ibuprofen
• sodium salts including ibuprofen and most of the other active ingredients mentioned above
• the alkali metal salts of such active ingredients are generally freely water-soluble but often have a bitter taste and are precipitated from acidic solutions frequently in lumpy form and/or with foam formation; the same occurs in the case of solid dosage forms as a result of the gastric acid. These active ingredients therefore easily lead to irritation of the stomach walls.
• EP-A1-369 228 has already proposed granulating 100 parts by weight of a water-soluble ibuprofen salt with 200 to 1000 parts by weight of vehicle, 30 to 80 parts by weight of stabilizer (for example polyvinylpyrrolidone, "PVP") and 10 to 100 parts by weight of an alkali metal carbonate, and mixing the resulting granules with 100 to 400 parts by weight of the acid component.
• PVP polyvinylpyrrolidone
• the aim here is to obtain the sodium salt in solution after dissolution of the effervescent tablet. This is achieved, inter alia, by virtue of the fact that the pH is in any case always above 6 in the case of the chosen composition.
• such a solution has an unpleasant taste, for example diclofenac sodium even has a bitter taste.
• very large amounts of PVP are required to prevent precipitation of the active ingredient as acid during effervescence.
• the alkali metal salt or lysinate coats the particles of the alkaline component of the effervescent system, for example sodium bicarbonate and/or sodium carbonate, and is covered in particular with further alkali metal carbonate.
• the active ingredient layers expediently also contain (per 100 parts by weight of active ingredient) at least 0.5 part by weight, preferably 1 to 3 parts by weight, of a surfactant, in particular docusate sodium or sodium laurylsulfate. Selecting the combination of very small amounts of stabilizer (or even no stabilizer at all) with surface-passivated components from the many possible formulations in the attempt to achieve the object was not obvious even to a person skilled in the art and required a large number of considerations.
• the precipitate according to the present invention is substantially finer than the form in which it would be possible to obtain a finely pulverulent active ingredient.
• the alkali metal salt or lysinate of the active ingredient acid first dissolves during the dissolution of the effervescent tablet or effervescent mixture, owing to the close contact with a sodium bicarbonate or a sodium carbonate particle; said active ingredient acid is precipitated only subsequently, in the solution prepared for drinking, by the acid component of the effervescent system, for example within 5 seconds, optionally even in colloidal form, but in any case in finely disperse form.
• the finely disperse particles remain suspended for a relatively long time and therefore give a liquid which is pleasant to drink.
• the acid no longer irritates the stomach walls, which are moreover protected by the buffer action of the effervescent system.
• the active ingredients according to the invention are generally those which are intended to be absorbed not in the acidic medium of the stomach but in the alkaline medium of the intestine.
• the finely disperse form of the active ingredient in the solution also limits the passage through the stomach to about 15 to 20 minutes, so that immediate absorption can take place on entry into the pylorus and the intestine, owing to the very large surface area of finely disperse or almost colloidal acid particles of the active ingredient.
• the alkali metal salt or lysinate of the active ingredient goes into solution briefly on dissolution of the effervescent tablet and whereby only thereafter (after a delay) the active ingredient is precipitated in acid form by the remaining acidic solution, which may have a pH of 4 to 5.5
• the alkali metal salt or lysinate of the active ingredient very intimately with the alkali metal carbonate, for example sodium bicarbonate or sodium carbonate, so that, at the instant of dissolution, alkaline protection is achieved around the particles, which delays the precipitation.
• the active ingredient salt is merely mixed with an effervescent base, since in this case there is immediately contact with the acid, for example citric acid, at the instant of dissolution.
• pharmaceutically or toxicologically acceptable surfactants such as, for example, docusate sodium or sodium laurylsulfate (dark-colored or pasty surfactants which are difficult to process are unsuitable)
• binders such as, for example, dextrin, polyvinylpyrrolidone or hydrocolloids, such as, for example, maltodextrin
• the suspension properties of the active ingredient acid in the liquid are greatly improved as a result.
• excessively large amounts of binder may cause undesirable foam formation and delay the dissolution of the effervescent tablet. The effect is also dependent on whether an aqueous or alcoholic solution is used.
• the mixture contains at least 1 part by weight, preferably 3 to 5, in particular not more than 20, parts by weight of binder or suspending agent, in particular polyvinylpyrrolidone.
• binder or suspending agent in particular polyvinylpyrrolidone.
• a surfactant is therefore also preferably used in order to achieve better wetting of the acid particles during dissolution.
• the binding of the active ingredient can be achieved in various ways:
• the alkali metal salt or lysinate is dissolved and the solution is applied to sodium bicarbonate; drying is then carried out; the active ingredient salt crystallizes out on the surface of the sodium bicarbonate crystal.
• the very finely powdered active ingredient is mixed with the sodium bicarbonate; both are agglomerated with a binder, for example dextrin.
• a binder for example dextrin.
• diclofenac sodium 25 parts are dissolved, with 10 parts of propylene glycol, 40 parts of sorbitol, 1 part of polyvinylpyrrolidone K30 and 0.5 part of a surfactant substance, in particular docusate sodium, in 40 parts of ethanol and 15 parts of water.
• a surfactant substance in particular docusate sodium
• This solution is applied to 350 parts of sodium bicarbonate and thoroughly distributed; this is followed by the addition of 100 parts of sodium carbonate, which first absorbs water and only then goes into solution, in order to improve the alkaline protection.
• the material is then dried in vacuo and sieved to the desired particle size of, for example, 0.1 to 0.5 mm.
• the granules are then mixed with an acidic effervescent base consisting of a solid, edible, organic, surface-passivated acid and, if required, pressed to give tablets.
• the surface passivation can be carried out in a manner known per se, for example as described in EP-B1-272 312 or WO93/00886.
• it is also possible to avoid the reaction between acid and carbonate in the passivation by coating or covering the surface of the acid crystals, for example of the citric acid, with a solution of sodium citrate and then applying to this coat sodium bicarbonate and/or sodium carbonate from a solution in the form of a coat.
• This application is particularly expediently effected in a vacuum mixing vessel and provides the best possible protection.
• diclofenac sodium 25 parts are mixed with 350 parts of sodium bicarbonate and granulated together with the following solution: 15 parts of dextrin, 1 part of PVP and 0.5 part of a surfactant substance are dissolved in 20 parts of ethanol and 20 parts of water. The product is then dried, sieved to 0.1-0.5 mm, depending on requirements, and finally further treated as in Example 1.
• 1400 parts by weight of crystalline citric acid and 200 parts by weight of powdered citric acid are heated to 60° C. in a vacuum mixer while stirring and are wet with 6 parts by weight of water. Thereafter, 200 parts by weight of sodium bicarbonate are added and allowed to react at the surface of the citric acid, after which 50 parts by weight of sodium carbonate are added. The product is dried in vacuo while stirring.
• the naproxen granules and the acid granules are mixed with one another, and sweetener, flavor and fillers are added. Mixing is then carried out for homogenization, and the granules are pressed to give tablets weighing 3.2 g.
• the tablet dissolves in about 80 seconds, the naproxen being distributed in the solution in the form of a fine suspension, at a pH of 4-4.5.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Public Health (AREA)
• Polymers & Plastics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Nutrition Science (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Food Science & Technology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• General Preparation And Processing Of Foods (AREA)
• Detergent Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Bakery Products And Manufacturing Methods Therefor (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=4238568

Family Applications (1)

Country Status (9)

Cited By (9)

Families Citing this family (11)

Citations (7)

Family Cites Families (3)

• 1994
  • 1994-09-05 EP EP94113877A patent/EP0642784B1/de not_active Expired - Lifetime
  • 1994-09-05 ES ES94113877T patent/ES2133454T3/es not_active Expired - Lifetime
  • 1994-09-05 DE DE59410143T patent/DE59410143D1/de not_active Expired - Lifetime
  • 1994-09-05 EP EP98110087A patent/EP0867426B1/de not_active Expired - Lifetime
  • 1994-09-05 AT AT98110087T patent/ATE219762T1/de active
  • 1994-09-05 AT AT94113877T patent/ATE180164T1/de active
  • 1994-09-05 DK DK94113877T patent/DK0642784T3/da active
  • 1994-09-05 DE DE9422239U patent/DE9422239U1/de not_active Expired - Lifetime
  • 1994-09-05 DE DE59408273T patent/DE59408273D1/de not_active Expired - Lifetime
  • 1994-09-06 CA CA002131515A patent/CA2131515C/en not_active Expired - Lifetime
  • 1994-09-07 US US08/301,970 patent/US5593693A/en not_active Expired - Lifetime
  • 1994-09-07 CN CN94113873A patent/CN1096279C/zh not_active Expired - Fee Related
  • 1994-09-07 JP JP6213623A patent/JPH07223937A/ja active Pending

Patent Citations (8)

Also Published As

Similar Documents

Legal Events